1. Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering
- Author
-
Xiaoqiang Huang, Yongqun He, Yang Zhang, Edison Ong, and Robin Pearce
- Subjects
Antigenicity ,T cell ,Protein design ,Biophysics ,Computational biology ,Biology ,Major histocompatibility complex ,Biochemistry ,Epitope ,Article ,03 medical and health sciences ,0302 clinical medicine ,Protein sequencing ,Antigen ,Structural Biology ,Epitope engineering ,Genetics ,Native state ,medicine ,030304 developmental biology ,ComputingMethodologies_COMPUTERGRAPHICS ,0303 health sciences ,EvoDesign ,Immunogenicity ,Rational design ,COVID-19 ,Structural vaccinology ,Computer Science Applications ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,biology.protein ,Target protein ,Spike glycoprotein ,Vaccine ,TP248.13-248.65 ,Biotechnology - Abstract
Graphical abstract, Highlights • Evolutionary design of new SARS-CoV-2 spike proteins by perturbing the core protein sequence without changing the surface conformation. • Computationally designed SARS-CoV-2 spike proteins contain additional MHC-II T cell promiscuous epitopes with enhanced T cell immunity. • Structurally designed SARS-CoV-2 spike proteins preserve function and B cell immunity. • The newly designed SARS-CoV-2 spike proteins can be explored as new COVID-19 vaccine candidates., The development of effective and safe vaccines is the ultimate way to efficiently stop the ongoing COVID-19 pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Built on the fact that SARS-CoV-2 utilizes the association of its Spike (S) protein with the human Angiotensin-converting enzyme 2 (ACE2) receptor to invade host cells, we computationally redesigned the S protein sequence to improve its immunogenicity and antigenicity. Toward this purpose, we extended an evolutionary protein design algorithm, EvoDesign, to create thousands of stable S protein variants that perturb the core protein sequence but keep the surface conformation and B cell epitopes. The T cell epitope content and similarity scores of the perturbed sequences were calculated and evaluated. Out of 22,914 designs with favorable stability energy, 301 candidates contained at least two pre-existing immunity-related epitopes and had promising immunogenic potential. The benchmark tests showed that, although the epitope restraints were not included in the scoring function of EvoDesign, the top S protein design successfully recovered 31 out of the 32 major histocompatibility complex (MHC) -II T cell promiscuous epitopes in the native S protein, where two epitopes were present in all seven human coronaviruses. Moreover, the newly designed S protein introduced nine new MHC-II T cell promiscuous epitopes that do not exist in the wildtype SARS-CoV-2. These results demonstrated a new and effective avenue to enhance a target protein’s immunogenicity using rational protein design, which could be applied for new vaccine design against COVID-19 and other human viruses.
- Published
- 2021